On the one hand, KIF18B was identified as a biomarker for HCC prognostic evaluation and immunotherapeutic response prediction via bioinformatic-based investigations, the up-regulated KIF18B mRNA expression was demonstrated to predict advanced TNM stage and elevated lymph node metastatic risk of HCC patients [96, 97]. This evidence concerns the gene KIF18B and hepatocellular carcinoma.